Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Lesinurad Intermediate. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel patent CN106478531B offers high-purity Lesinurad intermediate synthesis with reduced environmental impact and scalable manufacturing for global supply chains.
Novel enzymatic N-demethylation route for Lesinurad intermediate. High yield, non-toxic reagents, scalable process for API manufacturing.
Advanced purification method for Lesinurad intermediate achieving over 99% HPLC purity. Cost-effective salt formation technology for reliable pharmaceutical supply chains.
Patent CN103524440A details a safer, thiophosgene-free route for Lesinurad intermediates, offering cost reduction and scalable manufacturing for gout therapeutics.
Novel patent CN105906576A offers toxic-free lesinurad intermediate synthesis. High yield 96.30% step ensures cost reduction and supply reliability for pharmaceutical manufacturing.
Patent CN105263913B details a safer thio-1,2,4-triazole synthesis route offering high purity and cost reduction in API manufacturing for global supply chains.
Patent CN111116501B details a novel catalytic method for synthesizing Lesinurad intermediates, eliminating chlorinated impurities and ensuring scalable API production.